Mayo Clinic researchers, in collaboration with the Centers for Disease Control and Prevention (CDC) and health officials from Minnesota, North Dakota and Wisconsin, have discovered a new bacterial species that causes Lyme disease in people. The new species has been provisionally named Borrelia mayonii. Prior to this finding, the only species believed to cause Lyme disease in North America was Borrelia burgdorferi.
In the paper published recently in The Lancet Infectious Diseases, Mayo Clinic scientists tested samples from U.S. patients from 2003 to 2014 for evidence of Lyme disease using a method called polymerase chain reaction (PCR). From 2012 to 2014, the researchers noticed unusual test results from 6 of 9,000 samples from residents of Minnesota, North Dakota and Wisconsin.
“Using a laboratory-developed test with a method called ‘melting temperature analysis,’ we detected six specimens that produced a PCR result that was clearly different from B. burgdorferi,” says Bobbi Pritt, MD, director of the Clinical Parasitology Laboratory at Mayo Clinic who is first author of the study. “Mayo Medical Laboratories, the reference laboratory at Mayo, has tested more than 100,000 patient samples from all 50 states over the past decade using our PCR assay, but we’ve only recently detected evidence of B. mayonii.”
Based on these findings, the researchers believe that the organism may have only recently emerged in the upper Midwestern U.S. “It is possible that this species has been present for even longer but at such low levels that it escaped detection,” adds Pritt.
As with B. burgdorferi, researchers believe that B. mayonii is transmitted to humans by the bite of an infected black-legged tick (otherwise known as the deer tick). Typical symptoms of Lyme disease include fever, headache, rash, neck pain, and arthritis in later stages. Unlike B. burgdorferi, however, B. mayonii causes an illness that appears to be associated with nausea and vomiting, diffuse rashes (rather than a single bull’s-eye rash), and a higher concentration of bacteria in the blood.
Patients infected with B. mayonii will test positive for Lyme disease with currently available U.S. Food and Drug Administration-cleared Lyme disease tests. In some instances, B. mayonii bacteria also may be seen on a blood smear. “Specific identification of the organism can be made by using the Mayo Clinic PCR test, which detects the DNA of the Lyme disease bacteria,” notes Pritt.
For treatment, the patients described in the study fully recovered using antibiotics commonly used to treat Lyme disease caused by B. burgdorferi. The CDC recommends that health care providers who are caring for patients infected with B. mayonii also follow the antibiotic regimen described by the Infectious Diseases Society of America.
Pritt adds, “At this time, there is no evidence that B. mayonii is present outside of the Upper Midwest. However, the public should continue to take the recommended precautions against tick bites, as Lyme disease and other tick-borne diseases are well-established in much of the Northeast.”
Source: Mayo Clinic
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.